PBYI Earnings

PBYI reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 55.00M against an estimate of 51.00M, resulting in a 6.86% surprise. The EPS was 0.17, surpassing the expected 0.06 by 183.33% . The stock experienced a 22.24% price change on the earnings day and a 1.84% change over the next five days, reflecting market reactions to the results.

Following PBYI's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 22.24% on the day of the release. Over the subsequent five days, it saw a 1.84% change. Historically, PBYI's stock price tends to shift by an average of +1.78% in the 10 days leading up to earnings and +9.01% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PBYI’s annual revenue to reach 69.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PBYI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PBYI's stock price typically moves by +1.78% in the 10 days before its earnings and +9.01% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 69.00M.

The earnings call reveals significant challenges, including a decline in total revenue and royalty revenue, competitive pressures, and regulatory risks. Although there is some positive news, like increased NERLYNX U.S. net sales, the overall sentiment is hindered by declining prescriptions, increased R&D costs, and financial pressures from debt obligations. The Q&A section indicates a cautious approach to spending and profitability, further reflecting concerns. These factors suggest a negative stock price movement over the next two weeks.